AbbVie becomes an obesity contender as it partners with Danish biotech Gubra in $350M upfront deal for amylin analog GUBamy, ...

Industry groups are looking to push government drug price negotiation and PBM reforms into a massive Republican domestic ...

Biotech investing saw growth in 2024, with RA Capital leading VCs. FDA cancels flu vaccine meeting, Pfizer hires ex-FDA ...

BridgeBio Oncology Therapeutics to go public via merger with Helix Acquisition Corp. II SPAC, led by Bihua Chen's Cormorant, ...

Praxis reported that its lead small molecule program failed a Phase 3 study on Friday morning, sending its stock price down ...

CHMP recommends approval of Regeneron's Lynozyfic, Krystal's Vyjuvek, Accord's trabectedin, Takeda's Deqsiga, and 16 label ...

William Pao, former Roche R&D leader and Pfizer CDO, now leads Revelio Therapeutics (formerly Launchpad) as CEO, joins ...

CDC investigating 5 hospitalizations in people 65+ for cardiac/neurologic events after receiving Valneva's Ixchiq chikungunya ...

RA Capital leads as most active venture player in private biotech rounds through 2024, with ARCH participating in fewer but ...

Kallyope's Phase 2 obesity trial shows K-757 and K-833 combo achieved 2.9% weight loss vs 0.2% for placebo. Results fall ...

More than a month after its most recent scheduled meeting was postponed, a panel advising the government on a federal ...

Eli Lilly will start selling additional single-dose vials of its weight loss drug Zepbound at a lower price for certain ...